Characterization of virus-like particles enables process reproducibility and product consistency. 

Therapeutic Moieties of the Future

Technology advances and collaboration push more therapies closer to commercialization.

Can Cell and Gene Therapies Achieve Their Full Potential? 

Plasma-based proteins and cell-based therapies have potential to address unmet medical needs.

Therapeutic Value of Blood Components

Topic

Shannon Parisotto, MBA, is the corporate senior vice president of Charles River Laboratories.

Articles

Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.  

Toxicology: Ensuring Drugs are Safe for People

Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.

Catalent to Acquire Delphi Genetics to Expand Plasmid DNA Capabilities 

With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library. 

Eurofins to Expand Drug Discovery Capabilities Through Beacon Discovery Acquisition

The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.

Eli Lilly to Collaborate with Rigel Pharmaceuticals for $960 Million 

The company has completed the expansion of its laboratory facilities to accommodate the development of APIs. 

Regis Technologies Completes Expansion of its Illinois Lab Facilities 

The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.

GSK and Vir Expand COVID-19 Therapeutics Collaboration to Include Influenza Therapies

The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.

Novartis and the Bill & Melinda Gates Foundation Team Up to Develop Gene Therapy for Sickle Cell Disease

Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.

Nanoform, Herantis Collaborate on Nasal Drug Delivery to the Brain of Biologics

Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.

AbbVie to Collaborate with Caribou Biosciences on CAR-T Cell Therapeutics

Smritie Sheth is scientific manager at SymphonyTech Biologics.

Ravindra Khare is CSO of SymphonyTech Biologics

Atul Khandekar is COO of SymphonyTech Biologics

Gulji­­t Chaudhuri is managing director, BioInnovat, New Delhi, India

Shilpa Jindani is medical director, Family Medicine, Thousand Oaks, CA.

Narendra Chirmule, PhD, is CEO at SymphonyTech Biologics.

Brinda Kakkar is senior resident, Bharati Vidyapeeth Medical College and Hospital.

Raman Govindrajan is director and CSO, Samrud Foundation for Health and Research, Bangalore, India.

Smita Kale is associate manager at the Venture Center, Pune, India.

V. Premnath is head, NCL Innovations at CSIR-NCL and director, Venture Center, Pune, India.

Ranganayaki Nagaraj is manager of the Venture Center, Pune, India.

A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis

A Systematic Evaluation of Risks and Mitigation Strategies for Convalescent Plasma Therapy for COVID-19

New approaches to clinical trials, spurred by the COVID-19 pandemic, have dramatically shortened development timeframes. Can these gains be sustained once conditions return to normal?

Boosting Drug Development

Rajika Jindani is a medical resident at University of Miami.

Soumya Paul is CEO at Pentavalent Biosciences.

Anurag S. Rathore is a professor in the Department of Chemical Engineering at the Indian Institute of Technology Delhi and a member of 

l's Editorial Advisory Board, Tel. +91.9650770650, asrathore@biotechcmz.com.

Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.

Platform-Specific Risk Assessment of SARS-CoV-2 Vaccines Using FMEA

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

Exploring the Therapeutic Value of Blood Components

Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.

Remote Monitoring and Big Data Advance Upstream Automation

Joshua Arias, joshua.arias@milliporesigma.com, is technical leader, BioReliance End to End Solutions, MilliporeSigma.

Mani Vinay Kumar Kotipalli is process engineer, Drug Substance Technology & Engineering, Amgen.

A unified scale-up approach, as presented here, can be applied to any unit operation.

A Unified Approach for Scaling Bioprocess Unit Operations

The new US offices will give the company the ability to support its US-based customers on site while continuing to collaborate with its global team.

Leukocare Opens Development Laboratories and Offices in Massachusetts 

The collaboration will focus on up to three types of lung and gastrointestinal cancers.

Boehringer Ingelheim and Enara Bio Partner on Cancer Immunotherapies

The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.

Precision Medicine Group Acquires Project Farma

The 17,000 m2 facility will serve as a process development and manufacturing site for Chinese companies developing medicines as well as multinationals with manufacturing requirements in China.

Cytiva Delivers Chinese Biomanufacturing Facility to Lonza

Under the terms of the agreement, operations will be initiated at Lonza’s Houston, TX Center of Excellence where Lonza will handle process development activities for late-clinical and commercial-scale GMP manufacturing of the cell therapy.